Breaking News Instant updates and real-time market news.

ADMS

Adamas Pharmaceuticals

$14.23

-0.16 (-1.11%)

08:42
08/25/17
08/25
08:42
08/25/17
08:42

Adamas Pharmaceuticals price target raised to $33 from $29 at JMP Securities

JMP Securities analyst Jason Butler raised his price target on Adamas after the FDA approved its GOCOVRI drug as an adjunctive treatment for Parkinson's disease patients. The analyst says that the drug's label is "broad." He keeps an Outperform rating on the stock.

ADMS Adamas Pharmaceuticals
$14.23

-0.16 (-1.11%)

11/23/16
JMPS
11/23/16
NO CHANGE
JMPS
Adamas could have positive read through from Allergan deal, says JMP Securities
After Adamas' partner, Allergan (AGN), agreed to buy Chase Pharmaceuticals, JMP Securities analyst Jason Butler thinks that the deal could have positive implications for Adamas Pharmaceuticals and its Alzheimer's treatment, Namzaric, a combination therapy which blocks a neutrotransmitter. The analyst says that the deal "reinforces Allergan's long-term commitment to neurotransmitter focused" Alzheimer;s treatments and provides the opportunity for Chase's drug to be combined with Namzaric. The analyst thinks that such a combined drug could gain additional market share. He keeps a $29 price target and an Outperform rating on Adamas.
08/09/17
COWN
08/09/17
NO CHANGE
Target $45
COWN
Outperform
Adamas Pharmaceuticals nearing valuation inflection, says Cowen
Cowen analyst Ken Cacciatore believes Adamas Pharmaceuticals' Parkinson's drug will be approved by late August as it is differentiated and addresses an unmet need. The analyst feels it should be a significant near term value creator and recommends investors add to positions. Cacciatore reiterated his Outperform rating and $45 price target on Adamas Pharmaceuticals shares.
08/17/17
JMPS
08/17/17
NO CHANGE
JMPS
Adamas Pharmaceuticals shares should be bought on weakness, says JMP Securities
JMP Securities analyst Jason Butler says that Adamas Pharmaceuticals shares should be bought on weakness ahead of the August 24 PDUFA date for its ADS-5102 drug. The analyst thinks that the weakness in the stock has been driven primarily by risk disclosures it made related to the approvability and product label of the drug. However, the analyst says that the warnings are "benign" and have no impact on the drug's approvability. He continues to believe that investors are underestimating the drug's outlook and keeps a $29 price target and an Outperform rating on the stock.
08/25/17
COWN
08/25/17
NO CHANGE
Target $55
COWN
Outperform
Adamas Pharmaceuticals price target raised to $55 from $45 at Cowen
Cowen analyst Ken Cacciatore raised his price target on Adamas Pharmaceuticals to $55 from $45 after the company received approval of its Parkinson's treatment expected to launch in 2018. He noted consultants have been consistent in their belief the drug is differentiated, addresses an unmet need, and will be a welcome addition to the Parkinson's treatment paradigm. Cacciatore reiterated his Outperform rating on Adamas shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.